For instance, polyarginine and its analog polyornithine significantly antagonized aggregation of a p53 DBD-derived sequence corresponding to the aggregation-nucleating subdomain and the aggregation-inducing R248Q mutation (p53248–257: QRPILTIITL) and inhibited the proliferation of aggregation-prone mutant p53-bearing cancer cells, which showed increased p21 expression that is indicative of reactivated p53, while having no adverse effect on the growth of WT p53 or p53-null cancer cells [163]. This evidence concerns the gene TP53 and cancer.